Ifosfamide in combination chemotherapy for sarcomas and testicular carcinomas.

Abstract

The efficacy of ifosfamide combination chemotherapy was studied in 164 patients, 94 with advanced testicular carcinoma and 70 with metastatic sarcoma. Ifosfamide was given at 40-60 mg/kg/day i.v. on five consecutive days every 3-4 weeks together with mesna prophylaxis with 8 mg/kg i.v. being used at 0, 4 and 8 h after ifosfamide administration. Of 70 sarcoma patients 57 were evaluable for response, of whom 49 had received prior chemotherapy. The overall response rate was 46% (26/57) including 3 complete (CR) and 14 partial remissions (PR). Ninety-four patients with germ cell tumours of the testis were treated. Of 16 seminoma patients 15 achieved CR or PR. Seventy-eight patients with nonseminomatous testicular cancer who had received previous chemotherapy were either treated with ifosfamide/etoposide (n = 63, remission rate: 30%) or ifosfamide/cisplatin (n = 15, CR + PR: 33%). These results indicate that ifosfamide alone or in combination is active in sarcomas, seminomas and teratomas and that further studies are warranted employing the drug in first-line regimens.

• Authors: N Niederle, M E Scheulen, M Cremer, J Schütte, C G Schmidt, S Seeber
• Journal: Cancer treatment reviews (Cancer Treat Rev) Vol. 10 Suppl A Pg. 129-35 (Sep 1983) ISSN: 0305-7372 [Print] Netherlands
• PMID: 6627239 (Publication Type: Journal Article)

Chemical References

• Cyclophosphamide
• Ifosfamide

Topics

• Adolescent
• Adult
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Cyclophosphamide (analogs & derivatives)
• Female
• Humans
• Ifosfamide (administration & dosage)
• Male
• Middle Aged
• Sarcoma (drug therapy)
• Testicular Neoplasms (drug therapy)